NUVLNuvalent Inc - Ordinary Shares - Class A
NUVL
Nuvalent Inc - Ordinary Shares - Class A462
Mkt Cap
$8.18BVolume
190,428.0052W High
$113.0252W Low
$63.56PE Ratio
-17.78NUVL Fundamentals
Price
$102.31Prev Close
$104.04Open
$104.7150D MA
$102.00Beta
1.13Avg. Volume
566,676.43EPS (Annual)
-$5.85P/B
6.52Rev/Employee
$0.00$5,939.61
Nuvalent to Present Pivotal Data from ALKOVE-1 Trial of Neladalkib in TKI Pre-treated Advanced ALK-positive NSCLC at the 2026 American Society of Clinical Oncology Annual Meeting
Nuvalent to Present Pivotal Data from ALKOVE-1 Trial of Neladalkib in TKI Pre-treated Advanced ALK-positive NSCLC at the 2026 American Society of Clinical Oncology Annual Meeting Nuvalent to Present...
PR Newswire·7d ago
HC Wainwright Reaffirms Buy Rating for Nuvalent (NASDAQ:NUVL)
HC Wainwright reiterated a "buy" rating and set a $155.00 price target on shares of Nuvalent in a report on Tuesday...
MarketBeat·7d ago
New Clinical and Preclinical Data for Investigational Candidate Zidesamtinib Presented at AACR Annual Meeting 2026
New Clinical and Preclinical Data for Investigational Candidate Zidesamtinib Presented at AACR Annual Meeting 2026 New Clinical and Preclinical Data for Investigational Candidate Zidesamtinib Presented at AACR Annual Meeting 2026 PR Newswire CAMBRIDGE, Mass., April 17, 2026 Zidesamtinib...
PR Newswire·11d ago
Nuvalent (NASDAQ:NUVL) Insider Henry Pelish Sells 3,093 Shares
Nuvalent, Inc. (NASDAQ:NUVL - Get Free Report) insider Henry Pelish sold 3,093 shares of Nuvalent stock in a transaction dated Thursday, April 9th. The stock was sold at an average price of $104.48, for a total transaction of $323,156.64. Following the transaction, the insider owned 65,604 shares...
MarketBeat·14d ago
Insider Selling: Nuvalent (NASDAQ:NUVL) Insider Sells 3,093 Shares of Stock
Nuvalent, Inc. (NASDAQ:NUVL - Get Free Report) insider Henry Pelish sold 3,093 shares of the firm's stock in a transaction dated Thursday, April 9th. The stock was sold at an average price of $104.48, for a total transaction of $323,156.64. Following the completion of the sale, the insider directly...
MarketBeat·15d ago
Nuvalent, Inc. (NASDAQ:NUVL) Given Average Rating of "Moderate Buy" by Analysts
Shares of Nuvalent, Inc. (NASDAQ:NUVL - Get Free Report) have earned an average rating of "Moderate Buy" from the seventeen analysts that are currently covering the firm, MarketBeat reports. One...
MarketBeat·18d ago
Nuvalent (NASDAQ:NUVL) CEO Sells $3,113,100.00 in Stock
Nuvalent, Inc. (NASDAQ:NUVL - Get Free Report) CEO James Richard Porter sold 30,000 shares of the stock in a transaction on Monday, April 6th. The shares were sold at an average price of $103.77, for...
MarketBeat·19d ago
James Richard Porter Sells 30,000 Shares of Nuvalent (NASDAQ:NUVL) Stock
Nuvalent, Inc. (NASDAQ:NUVL - Get Free Report) CEO James Richard Porter sold 30,000 shares of the firm's stock in a transaction dated Monday, April 6th. The stock was sold at an average price of...
MarketBeat·20d ago
Nuvalent's (NUVL) Outperform Rating Reaffirmed at Wedbush
Wedbush reiterated an "outperform" rating and issued a $125.00 price target on shares of Nuvalent in a report on Wednesday...
MarketBeat·20d ago
Nuvalent Announces NDA Submission For Neladalkib
(RTTNews) - Nuvalent, Inc. (NUVL) announced the submission to the FDA of the company's NDA for neladalkib, an investigational ALK-selective inhibitor, in TKI pre-treated advanced ALK-positive NSCLC. The application is based on data in TKI pre-treated patients with advanced ALK-po...
Nasdaq News: Markets·21d ago
<
1
2
...
>